Sysmex Corporation (SSMXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sysmex Corporation (SSMXF) trades at $8.25 with AI Score 50/100 (Grade B). Sysmex Corporation develops, manufactures, and sells diagnostic instruments, reagents, and software. Market cap: $5.13B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SSMXF: SSMXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SSMXF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SSMXF: 3/7 perspectives are bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Sysmex Corporation (SSMXF) Healthcare & Pipeline Overview
Sysmex Corporation, a global leader in medical diagnostics, provides advanced instruments, reagents, and software solutions for hematology, immunochemistry, and flow cytometry. With a strong presence in Japan and exports to approximately 190 countries, Sysmex supports healthcare providers with innovative diagnostic technologies and lab assay services.
What Is the Investment Thesis for SSMXF?
Sysmex Corporation presents a compelling investment case based on its established market position, consistent profitability, and growth opportunities in the medical diagnostics sector. With a P/E ratio of 24.5 and a profit margin of 8.9%, the company demonstrates financial stability. A dividend yield of 2.48% provides an additional incentive for investors. Key growth catalysts include expansion in regenerative medicine and biodevices, coupled with the increasing demand for advanced diagnostic solutions globally. However, investors may want to evaluate potential risks such as regulatory changes and competition from established players like CNVVF and CNVVY.
Based on FMP financials and quantitative analysis
SSMXF Key Highlights
- Market capitalization of $5.13B reflects Sysmex's significant presence in the medical diagnostics market.
- Gross margin of 51.9% indicates strong pricing power and efficient cost management.
- Profit margin of 8.9% demonstrates consistent profitability in a competitive industry.
- Dividend yield of 2.48% offers a steady income stream for investors.
- Beta of 0.66 suggests lower volatility compared to the overall market.
Who Are SSMXF's Competitors?
SSMXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVVF ConvaTec Group Plc | $2.73 | +0.00% | $5.32B | 49 |
| CNVVY ConvaTec Group Plc | $11.74 | +0.41% | $5.74B | 43 |
| ESAIY Eisai Co., Ltd. | $6.66 | +2.78% | $7.52B | 55 |
| ESALF Eisai Co., Ltd. | $25.00 | +0.00% | $7.05B | 61 |
| GIFOF Grifols, S.A. | $8.85 | +0.00% | $8.70B | 52 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SSMXF's Key Strengths?
- Strong market position in hematology diagnostics.
- Global distribution network.
- Proprietary technology and intellectual property.
- Recurring revenue from reagent sales and service contracts.
What Are SSMXF's Weaknesses?
- Dependence on the healthcare industry and government regulations.
- Exposure to currency fluctuations.
- Limited presence in certain emerging markets.
- Potential for product recalls or liability claims.
What Could Drive SSMXF Stock Higher?
- Expansion in regenerative medicine and biodevices markets.
- Development and commercialization of new diagnostic instruments and reagents.
- Growth in digital medicine solutions and remote patient monitoring technologies.
What Are the Key Risks for SSMXF?
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
- Intense competition from established players and new entrants.
- Product recalls or liability claims.
What Are the Growth Opportunities for SSMXF?
- Expansion in Regenerative Medicine: Sysmex is actively involved in the research, development, manufacture, and sale of regenerative medicine products. The regenerative medicine market is projected to reach $50 billion by 2028, driven by advancements in cell therapies and tissue engineering. Sysmex's expertise in cell analysis and diagnostics positions it well to capitalize on this growth opportunity, potentially leading to new revenue streams and enhanced market share.
- Growth in Biodevices: Sysmex develops, manufactures, and sells biodevices, catering to the increasing demand for innovative medical devices. The global biodevices market is expected to reach $400 billion by 2027, driven by technological advancements and the growing need for minimally invasive procedures. Sysmex's focus on research and development allows it to introduce cutting-edge biodevices, strengthening its competitive edge and driving revenue growth.
- Digital Medicine Solutions: Sysmex is involved in the development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine. The digital health market is projected to reach $660 billion by 2025, driven by the increasing adoption of telehealth, remote patient monitoring, and electronic health records. Sysmex's investment in digital medicine allows it to offer integrated diagnostic solutions, improving patient outcomes and driving efficiency for healthcare providers.
- Geographic Expansion: Sysmex exports its products to approximately 190 countries, indicating a significant global presence. However, there is still potential for further geographic expansion, particularly in emerging markets with growing healthcare infrastructure. By strategically targeting these markets, Sysmex can increase its market share and diversify its revenue streams, mitigating risks associated with regional economic fluctuations.
- Strategic Partnerships and Acquisitions: Sysmex can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and enter new markets. Collaborating with or acquiring companies with complementary expertise can accelerate innovation and drive synergistic growth. For example, acquiring a company specializing in molecular diagnostics could strengthen Sysmex's position in the personalized medicine market.
What Opportunities Does SSMXF Have?
- Expansion into new diagnostic areas, such as molecular diagnostics and point-of-care testing.
- Growth in emerging markets with increasing healthcare spending.
- Strategic partnerships and acquisitions to expand product portfolio.
- Development of digital health solutions and remote patient monitoring technologies.
What Threats Does SSMXF Face?
- Intense competition from established players and new entrants.
- Technological obsolescence and the need for continuous innovation.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
What Are SSMXF's Competitive Advantages?
- Strong brand reputation and established market position in hematology diagnostics.
- Extensive global distribution network reaching approximately 190 countries.
- Proprietary technology and intellectual property in diagnostic instruments and reagents.
- High switching costs for customers due to the integration of Sysmex's instruments and software into their workflows.
What Does SSMXF Do?
Founded in 1968 as TOA Medical Electronics Co., Ltd. and rebranded as Sysmex Corporation in 1998, the company has evolved into a key player in the global medical diagnostics industry. Headquartered in Kobe, Japan, Sysmex develops, manufactures, and sells a comprehensive range of diagnostic instruments, reagents, and related software. Its product portfolio includes three-part and five-part white blood cell differentiation instruments for hematology, automated urine particle analyzers, blood coagulation analyzers, and immunochemistry systems. Sysmex also offers flow cytometers for diagnosing leukemia, malignant lymphoma, and HIV/AIDS, as well as cancer lymph node metastasis testing systems. Beyond instrumentation, Sysmex provides lab assay services and develops software for diagnostic information systems. The company serves a diverse customer base, including national and private hospitals, universities, research institutes, and other medical institutions, exporting its products to approximately 190 countries.
What Products and Services Does SSMXF Offer?
- Develops and manufactures diagnostic instruments for hematology.
- Produces reagents used in medical testing.
- Creates software for diagnostic information systems.
- Offers automated urine particle analyzers.
- Provides automated blood coagulation analyzers.
- Develops flow cytometers for diagnosing diseases like leukemia and HIV/AIDS.
- Offers cancer lymph node metastasis testing systems.
- Provides lab assay services.
How Does SSMXF Make Money?
- Sales of diagnostic instruments to hospitals, clinics, and research institutions.
- Recurring revenue from the sale of reagents used with their instruments.
- Software licensing and maintenance fees.
- Service contracts for instrument maintenance and support.
What Industry Does SSMXF Operate In?
Sysmex Corporation operates in the medical instruments and supplies industry, which is characterized by technological innovation, stringent regulatory requirements, and increasing demand for advanced diagnostic solutions. The global medical devices market is projected to reach $600 billion by 2025, driven by an aging population, rising prevalence of chronic diseases, and advancements in diagnostic technologies. Sysmex competes with companies like CNVVF, CNVVY, ESAIY, ESALF, and GIFOF, focusing on hematology, immunochemistry, and flow cytometry solutions.
Who Are SSMXF's Key Customers?
- National and other public hospitals.
- Private hospitals.
- Universities.
- Research institutes.
- Other medical institutions.
FY2026 estForward Outlook
Wall Street analysts project Sysmex Corporation revenue of about $501.30B for fiscal 2026, with EPS near $64.46. The estimate reflects 15 contributing analysts.
SSMXF Valuation & Market Position
With a $5.13B market cap, Sysmex Corporation sits in the mid-cap segment of the market. Relative to its peer group, SSMXF's quantitative score of 50/100 is roughly in line with the peer average of 52/100.
ROE 7%Key Financial Metrics
Return on equity for Sysmex Corporation stands at 7.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.0%, showing how much profit it generates from its asset base. SSMXF trades at a trailing price-to-earnings ratio of 24.50, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Sysmex Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.91 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Sysmex Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Kobe, JP. The company is led by CEO Hisashi Ietsugu. SSMXF has traded publicly since 2009.
SSMXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Strong market position in hematology diagnostics.
- Global distribution network.
- Proprietary technology and intellectual property.
- Recurring revenue from reagent sales and service contracts.
Bear Case
- Dependence on the healthcare industry and government regulations.
- Exposure to currency fluctuations.
- Limited presence in certain emerging markets.
- Potential for product recalls or liability claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SSMXF Latest News
No recent news available for SSMXF.
SSMXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SSMXF.
Price Targets
Wall Street price target analysis for SSMXF.
SSMXF MoonshotScore
What does this score mean?
The MoonshotScore rates SSMXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hisashi Ietsugu
Unknown
Information on Hisashi Ietsugu's background is not available in the provided data. Therefore, a detailed biography cannot be provided. Further research would be needed to gather information on his career history, education, and previous roles.
Track Record: Due to the lack of available information on Hisashi Ietsugu's background, it is not possible to provide a detailed account of his track record, key achievements, strategic decisions, or company milestones under his leadership. Further research is required.
SSMXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and there is no minimum financial standard required for inclusion. This tier often includes shell companies, companies in bankruptcy, and companies that are unwilling or unable to provide current financial information.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in SSMXF.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- The OTC Other tier carries a higher risk of fraud or manipulation compared to listed exchanges.
- Lack of regulatory oversight increases the potential for mismanagement or unethical behavior.
- The company may be subject to delisting or trading suspensions due to non-compliance with OTC market rules.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Evaluate the company's corporate governance practices.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Sysmex Corporation is an established company founded in 1968.
- The company has a global presence, exporting products to approximately 190 countries.
- Sysmex Corporation has a market capitalization of $5.13B.
- The company has a positive profit margin of 8.9%.
Sysmex Corporation Healthcare Stock: Key Questions Answered
What does Sysmex Corporation do?
Sysmex Corporation is a global leader in the development, manufacture, and sale of diagnostic instruments, reagents, and software for the healthcare industry. The company's primary focus is on hematology, immunochemistry, and flow cytometry, providing solutions for in vitro diagnostics. Sysmex's products are used in hospitals, clinics, and research institutions to analyze blood, urine, and other bodily fluids, aiding in the diagnosis and monitoring of various diseases and conditions. The company also offers lab assay services and digital medicine solutions.
What are the main risks for SSMXF?
The main risks for SSMXF include intense competition in the medical diagnostics industry, potential changes in healthcare regulations and reimbursement policies, and economic downturns that could reduce healthcare spending. Additionally, the company faces risks related to technological obsolescence and the need for continuous innovation to maintain its competitive edge. Product recalls or liability claims could also negatively impact Sysmex's financial performance and reputation. As an OTC-traded stock, SSMXF carries additional risks related to liquidity and transparency.
What are the key factors to evaluate for SSMXF?
Sysmex Corporation (SSMXF) holds an AI score of 50/100 (moderate). P/E: 24.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SSMXF data refresh on this page?
SSMXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SSMXF's recent stock price performance?
Sysmex Corporation (SSMXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in hematology diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SSMXF overvalued or undervalued right now?
Sysmex Corporation (SSMXF) trades at 24.5x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SSMXF?
Before investing in Sysmex Corporation (SSMXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SSMXF to a portfolio?
Key strength of Sysmex Corporation (SSMXF): Strong market position in hematology diagnostics. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on CEO's background and track record is limited.
- AI analysis is pending, so analyst consensus is not available.